CHA: Neopterin Dosage in the Eye
Study Details
Study Description
Brief Summary
The purpose of the study is to determine whether neopterin can be dosed in the fluid of the eye's anterior chamber for patient with non-inflammatory and non-infectious ophthalmic pathology.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
The study will be explained to subjects who are about to undergo ophthalmologic surgery. They will sign an informed consent and be included in the study. Urine sample will be collected specifically for the study. Eye's anterior chamber fluid will also be collected during the surgery as it is the usual practice (the sample is used for the neopterin dosage instead of being thrown away).
These samples will be centrifuged, frozen in a -80° C freezer. At the end of the study, all the samples will be sent to the central Lab for the neopterin dosage analysis. Results will be communicated to the principal investigator afterward.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Neopterin Dosage Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis |
Biological: Samples
Eye's anterior chamber fluid and urines are sampled for posterior neopterin analysis
|
Outcome Measures
Primary Outcome Measures
- Detection and dosage of neopterin in the eye [3 month]
HCL will detect and dose the neopterin in the eye's anterior chamber fluid
Secondary Outcome Measures
- Neopterin concentration comparison between study values and reference value. [3 month]
The reference values are standards established by the Neurobiology Lab from Lyon CHU which is the central lab that will performed the neopterin dosages.
- False positives identification and elimination. [3 month]
False positives will be determined by calibration of creatinine dosage in eye and urine samples.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years-old
-
Non inflammatory or non infectious ophthalmic pathology requiring puncture of eye's anterior chamber fluid.
-
Minimum of 200 microliter sample
-
Immunocompetent subjects
-
Signed and dated informed consent
-
Samples management in accordance with the pre-analytical conditions specified in the protocol
Non-inclusion criteria:
-
Age < 18 years-old
-
Subjects treated with intraocular corticoids, antibiotics or anti-inflammatory, locally or in systemic injection, prior to inclusion.
Exclusion Criteria:
-
Subjects who exercised his right of withdrawal
-
Study suspended on principal investigator, sponsor or health authorities' demand.
-
Deceased subjects
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Centre Hospitalier Intercommunal Toulon La Seyne sur Mer | Toulon | Var | France | 83200 |
Sponsors and Collaborators
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
- Hospices Civils de Lyon
Investigators
- Principal Investigator: Chaker Nefzaoui, doctor, Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
- Study Chair: Anélia Benarrosh, doctor, Centre Hospitalier Intercommunal Toulon La Seyne sur Mer
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2017-CHITS-02
- 2017-A00183-47